Delivery Order HHSN261201200021I-HHSN26100007

This is a $1,686,205.95 delivery order contract awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a randomized pre-surgical clinical trial evaluating alternative dosing regimens of the cancer drug exemestane in postmenopausal women with early-stage estrogen receptor-positive breast cancer. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early phase clinical research on new...

The National Cancer Institute (NCI) awarded a $1,366,178.15 delivery order contract to the University of Wisconsin System to conduct a pilot study of daily exemestane in women with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or grade 1 endometrial cancer. This contract is part of the NCI's Cancer Prevention Agent Development Program, which focuses on early-phase clinical research. The contract does not have a set-aside designation and will run through...

This is a contract awarded by the National Cancer Institute (NCI), an institute within the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center. The $2,186,264.78 contract is for a randomized, double-blind, placebo-controlled study of a topical breast cancer prevention agent, 4-hydroxytamoxifen gel, in women with dense breast tissue. This contract was issued under the NCI's Cancer Prevention Agent Development Program, which supports early phase clinical...

The University of Texas M.D. Anderson Cancer Center has been awarded a $912,585 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle to repurpose the macrolide antibiotic clarithromycin for the prevention of lung and breast cancer. The work will be performed under the PREVENT Program's PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS major program code, with the goal of assessing clarithromycin's preclinical efficacy and...

This federal contract was awarded by the National Cancer Institute, part of the Department of Health and Human Services, to the University of Alabama at Birmingham (UAB) to evaluate whether a concurrent retinoid X receptor agonist can enhance the efficacy of the HER2-IGFPB2-IGFLR vaccine in eliminating existing ductal carcinoma in situ and preventing progression of invasive breast cancer. The contract, valued at $930,464.00, is a delivery order under the PREVENT Cancer Program, a preclinical...

This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...

This is a firm fixed-price delivery order contract awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "Targeted Casein Kinase Inhibition as a Breast Cancer Prevention" research project. The $505,743.00 contract, which has no set-aside designation, was awarded on June 20, 2017 and is scheduled for completion by December 31, 2019. The contract falls under...

This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer". The potential value of the contract is $492,314.00. The work is being performed under the National Cancer Institute's "PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS" major...

This is a federal contract award from the National Cancer Institute (NCI) to Northwestern University, a private research university, for a Phase I clinical trial to evaluate the dermal tolerability and safety of an endoxifen gel in women undergoing breast surgery. The contract, which is part of NCI's Cancer Prevention Agent Development Program, has a ceiling value of $481,539.10 and a period of performance through August 31, 2023. Northwestern University is the prime contractor, with...

This federal contract award, valued at $2,817.72, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Femara tablets, a medication used to treat breast cancer, with an ultimate completion date of September 12, 2023. This contract award is not designated as a set-aside, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare...